Levetiracetam
Tocris Bioscience, part of Bio-Techne | Catalog # 2839
Binds SV2A; antiepileptic
Key Product Details
Description
Binds SV2A; antiepileptic
Alternative Names
Keppra,UCB L059
Product Description
Levetiracetam is an antiepileptic that displays distinctive properties from conventional antiepileptic drugs. Displays potent seizure protection in animal models of chronic epilepsy but lacks activity in acute seizure models. Binds synaptic vesicle protein 2A (SV2A) and inhibits Na+-dependent Cl-/HCO3- exchange. In a mouse model of Alzheimer's disease, Levetiracetam rescues levels of presynaptic vesicle fusion and neurotransmitter release, reduces Aβ42 and APP levels and decreases deposits of amyloid plaque; in vitro Levetiracetam inhibits Aβ-induced glutamate from astrocytes.Product Specifications
Molecular Weight
170.21
Formula
C8H14N2O2
Storage
Store at RT
Purity
≥98% (HPLC)
Chemical Name
(2S)-(2-Oxopyrrolidin-1-yl)butyramide
CAS Number
102767-28-2
PubChem ID
5284583
InChI Key
HPHUVLMMVZITSG-LURJTMIESA-N
SMILES
O=C1N([C@@H](CC)C(N)=O)CCC1
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Solubility
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| water | 17.02 | 100 | |
| DMSO | 17.02 | 100 |
Preparing Stock Solutions
for Levetiracetam
The following data is based on the product molecular weight 170.21
Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 5.88 mL | 29.38 mL | 58.75 mL |
| 5 mM | 1.18 mL | 5.88 mL | 11.75 mL |
| 10 mM | 0.59 mL | 2.94 mL | 5.88 mL |
| 50 mM | 0.12 mL | 0.59 mL | 1.18 mL |
Calculators
Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Background References
References are publications that support the biological activity of the product.
- Rao and Savas Levetiracetam treatment normalizes levels of presynaptic endocytosis machinery and restores nonamyloidogenic APP processing in App knock-in mice J.Proteome Res. 2021 PMID: 34106705
- Sanz-Blasco Levetiracetam inhibits oligomeric Aβ-induced glutamate release from human astrocytes. Neuroreport 2016 PMID: 27183239
- Sanchez Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc.Natl.Acad.Sci. USA 2012 PMID: 22869752
- Lynch The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug LeveT. Proct.Natl.Acad.Sci. USA 2004 PMID: 15210974
- Ueda Effect of LeveT on molecular regulation of hippocampal glutamate and GABA transporters in rats with chronic seizures induced by amygdalar FeCl3 injection. Brain Res. 2007 PMID: 17408599
- Smedt LeveT: the profile of a novel anticonvulsant drug - part I: preclinical data. CNS Drug Rev. 2007 PMID: 17461889
Product Specific Notices for Levetiracetam
For research use only
Loading...
Loading...